
PALISADE BIO, INC.
100
Recent developments highlight Palisade Bio's advancement of PALI-2108 through clinical milestones, regulatory clearances, and strategic appointments, alongside financial activities supporting ongoing development.
- Palisade Bio dosed the first patient in its Phase 2b ulcerative colitis trial, with data anticipated in Q4 2027 [N1].
- Early clinical activity of PALI-2108 was reported in Crohn's disease, supporting ongoing Phase 2 trials [N2].
- The company presented data supporting Phase 2 trials in inflammatory bowel disease, reinforcing clinical development progress [N3].
- Raymond James initiated coverage of Palisade Bio with an outperform rating, reflecting positive market interest [N4].
- Palisade Bio advanced PALI-2108 into Phase II trials for ulcerative colitis and Crohn’s disease [N5].
- Health Canada granted clearance for the Phase 2 ASCENTRA-UC study [N6].
- The FDA cleared the IND application for PALI-2108 in Crohn's disease, enabling Phase 2 trial initiation [N7].
- The company reported an expanded net loss in Q2 and plans Phase 2 ASCENTRA-UC trial enrollment in H2 2026 [N8].
- Palisade Bio appointed leading global IBD experts to its clinical advisory board to enhance clinical strategy [N1].
- An agreement was announced to exercise existing warrants and raise approximately $3.9 million, supporting financial resources [N1].
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon to treat inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Its lead candidate, PALI-2108, is engineered for local bacterial bioactivation to maximize efficacy and minimize systemic side effects. The company has completed Phase 1 clinical trials demonstrating safety and pharmacokinetics in healthy volunteers and UC patients, and has initiated Phase 2 trials globally following regulatory clearances. Palisade Bio operates under a license agreement with Giiant Pharma for key intellectual property and relies on third-party contract manufacturers for drug supply. The company is advancing clinical programs targeting both inflammatory and fibrotic components of IBD, including fibrostenotic Crohn's disease (FSCD), an area with significant unmet medical need. Financially, Palisade Bio maintains strong liquidity with over $113 million in cash and equivalents as of September 30, 2026, supporting ongoing clinical development activities.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing PALI-2108, a next-generation oral PDE4 inhibitor prodrug targeting inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The company has advanced PALI-2108 through Phase 1 clinical trials demonstrating safety and early clinical activity, and has initiated Phase 2 trials following FDA and Health Canada clearances. Financially, as of September 30, 2026, Palisade Bio held $113.6 million in cash and equivalents with a current ratio of 20.16, reflecting strong liquidity despite ongoing net losses. The company faces typical clinical development risks including regulatory approvals, patient enrollment, and reliance on third-party suppliers. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Palisade Bio's lead candidate, PALI-2108, has demonstrated promising preclinical and early clinical data indicating dual anti-inflammatory and anti-fibrotic effects, addressing significant unmet needs in IBD and FSCD. The company's targeted delivery approach may offer improved tolerability and convenience over existing therapies. Successful progression through Phase 2 trials with positive clinical outcomes could validate its precision medicine strategy and support regulatory approvals. Strategic collaborations and a strong intellectual property position enhance its development capabilities. Robust liquidity supports ongoing clinical programs and potential expansion of the pipeline.
Palisade Bio faces substantial risks typical of clinical-stage biopharmaceutical companies, including the possibility that PALI-2108 may not demonstrate sufficient efficacy or safety in larger, controlled Phase 2 trials. Regulatory approvals are uncertain and may be delayed or denied. Patient enrollment challenges and operational demands of concurrent global trials could impact timelines and costs. Dependence on third-party manufacturers and CROs introduces supply and execution risks. Intellectual property disputes or license termination could disrupt development. The company has a history of net losses and may require additional capital, which could dilute shareholders or constrain operations. Competition in the IBD market is intense, with alternative therapies potentially limiting commercial opportunity.
Palisade Bio's moat is primarily based on its proprietary oral PDE4 inhibitor prodrug technology designed for targeted delivery and local activation in the lower intestine, which aims to improve therapeutic index and reduce systemic side effects compared to existing PDE4 inhibitors. The company’s focus on both inflammatory and fibrotic aspects of IBD, including FSCD where no effective pharmacologic treatments currently exist, positions it in a niche with high unmet medical need. Its license agreement with Giiant Pharma provides access to critical intellectual property, and its biomarker-driven precision medicine approach may enhance patient selection and clinical response rates. However, as a clinical-stage company, its moat is contingent on successful clinical development, regulatory approvals, and eventual commercialization in a competitive IBD treatment landscape.
• Clinical Development Risks: PALI-2108 is in early clinical stages with inherent uncertainties in demonstrating safety and efficacy in larger trials. Failure to meet clinical endpoints or delays in trial completion could materially impact the company.
• Regulatory Approval Risks: Obtaining regulatory approvals from the FDA, Health Canada, and other authorities is uncertain and may be delayed or denied, affecting the ability to commercialize product candidates.
• Intellectual Property Risks: The company depends on license agreements, particularly with Giiant Pharma, for critical patents. Termination or disputes could impair development and commercialization.
• Operational and Supply Risks: Reliance on third-party CROs and manufacturers introduces risks related to quality, supply continuity, and compliance with regulatory standards.
• Financial Risks: The company has a history of net losses and expects to continue incurring losses. Additional capital may be required, which could dilute existing shareholders or limit operational flexibility.
• Market and Competitive Risks: The IBD treatment market is competitive with existing and emerging therapies. PALI-2108 must demonstrate differentiation and acceptance by physicians, payors, and patients.
Business trends: Advancement of PALI-2108 through Phase 2 clinical trials targeting ulcerative colitis and Crohn's disease, with a focus on addressing unmet needs in inflammatory and fibrotic bowel diseases.
Execution milestones: Completion of Phase 1 studies demonstrating safety and early activity, initiation and patient dosing in Phase 2 ASCENTRA-UC trial, regulatory clearances from FDA and Health Canada, and strategic appointments to clinical advisory board.
Key risks: Clinical trial uncertainties including efficacy and safety outcomes, regulatory approval challenges, reliance on intellectual property licenses, patient enrollment and operational execution risks, and financial sustainability during ongoing development.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs targeted to the terminal ileum and colon for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD) [S1].
- The lead clinical product candidate is PALI-2108, designed for targeted delivery and local bacterial bioactivation in the lower intestine to reduce systemic side effects and improve therapeutic index [S1].
- PALI-2108 has demonstrated dose-dependent efficacy in UC mouse models and shows dual anti-inflammatory and anti-fibrotic properties relevant to fibrostenotic Crohn's disease (FSCD) [S1].
- The company completed a Phase 1 clinical study of PALI-2108 including healthy volunteers and UC patients, meeting primary endpoints of safety, tolerability, and pharmacokinetics, with early signals of clinical activity in UC patients [S1].
- An exploratory Phase 1b cohort in FSCD was conducted, showing favorable safety, pharmacodynamics, and early clinical activity signals in five patients [S1].
- The FDA cleared Investigational New Drug (IND) applications for PALI-2108 enabling initiation of global Phase 2 ASCENTRA-UC and ASCENTRA-CD clinical trials; the first patient was dosed in the Phase 2 ASCENTRA-UC trial on October 27, 2026 [S1].
- The company has a research collaboration and license agreement with Giiant Pharma, which grants rights to patents and technology related to PALI-2108; compliance with this agreement is critical to ongoing development [S1].
- Manufacturing and supply rely on third-party contract development and manufacturing organizations (CDMOs and CMOs) selected for quality and regulatory compliance [S1].
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $113.6 million, current assets of $117.5 million, current liabilities of $5.8 million, a current ratio of 20.16, and a net loss of $14.6 million for the nine months ended September 30, 2026 [S2].
- The company has a history of net operating losses and expects to continue incurring losses during development [S2].
- Significant risks include clinical development uncertainties, regulatory approvals, patient enrollment challenges, reliance on third-party suppliers and CROs, intellectual property license dependencies, and competition in the IBD treatment space [S2].
- Recent news highlights include dosing the first patient in the Phase 2b ulcerative colitis trial with data anticipated in Q4 2027, early activity signals of PALI-2108 in Crohn's disease, and multiple positive clinical data presentations supporting Phase 2 trials [N1][N2][N3].
- The company has received Health Canada clearance for the Phase 2 ASCENTRA-UC study and FDA clearance for the IND in Crohn's disease [N6][N7].
- Multiple analyst firms have initiated coverage with positive recommendations, reflecting market interest [N4].
- The company has appointed leading global IBD experts to its clinical advisory board to enhance clinical strategy [N1].
- The company announced an agreement to exercise existing warrants and raise approximately $3.9 million in July 2025 [N1].
Generated 2026-11-11
- S1 | 2026-03-20 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-10-29 | www.nasdaq.com | Palisade Doses First Patient In Phase 2b Ulcerative Colitis Trial; Data Expected Q4 2027 | https://www.nasdaq.com/articles/palisade-doses-first-patient-phase-2b-ulcerative-colitis-trial-data-expected-q4-2027
- N2 | 2026-10-20 | www.nasdaq.com | Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's Disease | https://www.nasdaq.com/articles/palisade-bio-rises-9-pali-2108-shows-early-activity-crohns-disease
- N3 | 2026-10-12 | www.nasdaq.com | Palisade Bio Presents PALI-2108 Data Supporting Phase 2 Trials In Inflammatory Bowel Disease | https://www.nasdaq.com/articles/palisade-bio-presents-pali-2108-data-supporting-phase-2-trials-inflammatory-bowel-disease
- N4 | 2026-10-09 | www.nasdaq.com | Raymond James Initiates Coverage of Palisade Bio with Outperform | https://www.nasdaq.com/articles/raymond-james-initiates-coverage-palisade-bio-outperform
- N5 | 2026-09-27 | www.nasdaq.com | Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s | https://www.nasdaq.com/articles/palisade-bio-advances-pali-2108-phase-ii-ulcerative-colitis-and-crohns
- N6 | 2026-09-23 | www.nasdaq.com | Palisade Wins Health Canada Clearance For Phase 2 ASCENTRA-UC Study | https://www.nasdaq.com/articles/palisade-wins-health-canada-clearance-phase-2-ascentra-uc-study
- N7 | 2026-09-23 | www.nasdaq.com | Palisade Bio Gets FDA Clearance For PALI-2108 IND In Crohn's Disease | https://www.nasdaq.com/articles/palisade-bio-gets-fda-clearance-pali-2108-ind-crohns-disease
- N8 | 2026-08-11 | www.nasdaq.com | Palisade Bio Q2 Net Loss Expands; Plans Phase 2 ASCENTRA-UC Trial Enrollment In H2 2026; Stock Down | https://www.nasdaq.com/articles/palisade-bio-q2-net-loss-expands-plans-phase-2-ascentra-uc-trial-enrollment-h2-2026-stock
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


